To our knowledge, this is the first clinical trial to demonstrate induction of antigen specific immune tolerance in any autoimmune disease. COUR’s platform of immune-modifying nanoparticles treats the root cause of immune-mediated disease unlike traditional approaches, which rely on toxic immune suppressants or avoidance strategies. We are a group of dedicated scientific, medical, and business professionals who are driven to...
To our knowledge, this is the first clinical trial to demonstrate induction of antigen specific immune tolerance in any autoimmune disease. COUR’s platform of immune-modifying nanoparticles treats the root cause of immune-mediated disease unlike traditional approaches, which rely on toxic immune suppressants or avoidance strategies. We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures of immune-mediated diseases. By focusing our research on the root cause of disease, we seek to provide treatments previously unavailable to doctors and their patients.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.